Drug Middlemen Aim to Avoid New Rules With Voluntary Changes
The strategy being used is similar to one deployed by health insurers earlier this year, when they pledged to cut red tape for approvals.
Photographer: Christopher Katsarov/BloombergPharmacy middlemen are working on a proposal to voluntarily change some of their business practices in an effort to avoid new regulation from the Trump administration, according to people familiar with the discussions.
The main lobbying group that represents so-called pharmacy benefit managers, the Pharmaceutical Care Management Association, has drafted proposals to bring to the Centers for Medicare and Medicaid Services, according to a document viewed by Bloomberg News.